Hinge Health (HNGE) is drawing attention after recent trading, with the stock closing at US$64.75 and showing double digit percentage moves over the past month and past 3 months. Investors are assessing what this pricing implies.

The recent 1 day share price return of 4.33% builds on 30 day and 90 day share price returns of 17.26% and 43.89% respectively, while the 1 year total shareholder return of 84.89% points to strong momentum over a longer window.

If you are comparing Hinge Health with other digital care and automation stories, it may be worth scanning AI focused healthcare stocks via the 39 healthcare AI stocks

With Hinge Health trading at US$64.75 against an analyst price target of US$75.80 and an indicated intrinsic discount of 77.09%, you have to ask: is there genuine upside here, or is the market already pricing in future growth?

Most Popular Narrative: 49.2% Overvalued

The most followed narrative pegs Hinge Health's fair value at $43.40, well below the recent close at $64.75. This sets up a clear valuation gap to unpack.

The assumed bearish price target for Hinge Health is $43.4, which represents up to two standard deviations below the consensus price target of $57.94. This valuation is based on what can be assumed as the expectations of Hinge Health's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.

Read the complete narrative. Read the complete narrative.

Curious what earnings path has to play out for that lower fair value to hold up, and how much margin expansion is baked in over time? The full narrative spells out the growth, profitability and valuation bridge that needs to line up for Hinge Health at this price.

Result: Fair Value of $43.40 (OVERVALUED)

However, strong gross margins of 85% and a reported 2025 free cash flow margin of 31%, along with 97% client retention and net dollar retention above 110%, could pressure this cautious view.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Cash Flows Tell a Different Story

The bearish narrative pegs fair value at US$43.40 and tags Hinge Health as overvalued at current prices. Yet our DCF model, which focuses on future cash flows, points to a value of US$183.76 and labels the stock undervalued. Which set of assumptions do you find more realistic?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Hinge Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With such split opinions on value, are you comfortable relying on one framework, or do you want to see the full picture yourself? Take a closer look at the potential upsides that investors are focused on by reviewing the 3 key rewards.

Looking for more investment ideas?

If you only focus on one stock, you risk missing out on other opportunities that could fit your goals better, so broaden your watchlist with targeted screeners.

• Spot potential bargains early by checking companies that appear to offer good value with the 47 high quality undervalued stocks.
• Prioritize resilience by reviewing stocks that pass strict balance sheet and fundamentals checks through the solid balance sheet and fundamentals stocks screener (46 results).
• Hunt for underfollowed opportunities by scanning a screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.